Novel precision medicine approaches and treatment strategies in hematological malignancies
Richard Rosenquist,Elsa Bernard,Tom Erkers,David W Scott,Raphael Itzykson,Philippe Rousselot,Jean Soulier,Martin Hutchings,Päivi Östling,Lucia Cavelier,Thoas Fioretos,Karin E. Smedby
DOI: https://doi.org/10.1111/joim.13697
2023-07-11
Journal of Internal Medicine
Abstract:Genetic testing has been applied for decades in clinical routine diagnostics of hematological malignancies to improve disease (sub)classification, prognostication, patient management and survival. In recent classifications of hematological malignancies, disease subtypes are defined by key recurrent genetic alterations detected by conventional methods (i.e., cytogenetics, FISH, and targeted sequencing). Hematological malignancies were also one of the first disease areas in which targeted therapies were introduced, the prime example being BCR::ABL1 inhibitors, followed by an increasing number of targeted inhibitors hitting the Achilles' heel of each disease, resulting in a clear patient benefit. Owing to the technical advances in high‐throughput sequencing, we can now apply broad genomic tests, including comprehensive gene panels or whole‐genome and whole‐transcriptome sequencing, to identify clinically important diagnostic, prognostic and predictive markers. In this review, we give examples of how precision diagnostics have been implemented to guide treatment selection and improve survival in myeloid (myelodysplastic syndrome, acute myeloid leukemia) and lymphoid malignancies (acute lymphoblastic leukemia, diffuse large B cell lymphoma, chronic lymphocytic leukemia). We discuss the relevance and potential of monitoring measurable residual disease using ultra‐sensitive techniques to assess therapy response and detect early relapses. Finally, we bring up the promising avenue of functional precision medicine, combining ex vivo drug screening with various omics technologies, to provide novel treatment options for patients with advanced disease. Although we are only in the beginning of the field of precision hematology, we foresee rapid development with new types of diagnostics and treatment strategies becoming available to the benefit of our patients. This article is protected by copyright. All rights reserved
medicine, general & internal